Reduction in Herpes Zoster Antiviral Use Since the Introduction of the Live-Attenuated Zoster Vaccine on Australia’s National Immunisation Program: A Population-Based Study from 1994 to 2019

Abstract Introduction Zostavax, the live-attenuated vaccine used to prevent herpes zoster (HZ), has been available to individuals aged 70 and 71–79 years (phased catch-up) via Australia’s National Immunisation Program (NIP) since 2016. There are limited data characterising the incidence of HZ at the...

Full description

Bibliographic Details
Main Authors: Sachin Phakey, Sophie L. Rogers, Anthony J. Hall, Lyndell L. Lim
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-01-01
Series:Infectious Diseases and Therapy
Subjects:
Online Access:https://doi.org/10.1007/s40121-022-00749-y